GlassScriptPhysician profile
Haydee B Docasar
NPI 1245343037
$854.22
in general payments reported to CMS, 2019-2025
15 companies · $38.02 in 2025
The $38.02 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.69 · 2020: $181 · 2021: $365 · 2022: $180 · 2023: $54.34 · 2025: $38.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $226.94 | 2020-2022 | |
| Abbvie INC. | $210.06 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $87.33 | 2021-2023 | |
| Pfizer INC. | $67.60 | 2020-2022 | |
| Merz North America, INC. | $49.50 | 2020-2025 | |
| Myovant Sciences INC. | $39.69 | 2021-2022 | |
| Evofem Biosciences, INC. | $35.03 | 2022 | |
| Avion Pharmaceuticals | $28.27 | 2022-2023 | Balcoltra |
| Organon LLC | $19.62 | 2022 | |
| Astellas Pharma US INC | $19.39 | 2023 | Veozah |
| Gilead Sciences, INC. | $16.22 | 2019 | |
| Novo Nordisk INC | $15.23 | 2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $14.12 | 2020 | |
| Lupin INC. | $12.70 | 2020 | |
| Exeltis, USA INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haydee Docasar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.